Brand and Other Names:Fosrenol
- Classes: PO4 Scavengers
Dosing & Uses
Dosage Forms & Strengths
Reduction of Serum Phosphate in ESRD Patients
Initial: 750-1500 mg/day PO in divided doses
Titrate by 750 mg increments q2-3Weeks until acceptable serum phosphate level attained
Doses up to 4500 mg were evaluated in clinical trials; most patients required a total daily dose between 1500-3000 mg to reduce plasma phosphate levels to <6.0 mg/dL
Take with or immediately after meals
Chewable tablet: Chew or crush tablet completely; do not swallow whole
- Sprinkle oral powder on a small quantity of applesauce or other similar food and consume immediately
- Do not open until ready to use
- Do not store oral powder for future use once mixed with food
- Oral powder is insoluble, do not attempt to dissolve in liquid for administration
- Consider using the oral powder formulation in patients with poor dentition, or who have difficulty chewing tablets
Serious - Use Alternative
Significant - Monitor Closely
Dialysis graft complication/occlusion
Allergic skin reactions
Use with caution in PUD, Crohn's disease, ulcerative colitis, bowel obstruction
Serious cases of gastrointestinal obstruction, ileus, subileus, gastrointestinal perforation and fecal impaction reported; risk factors for gastrointestinal obstruction and gastrointestinal perforation in patients taking chewable tablets include altered gastrointestinal anatomy (e.g., diverticular disease, peritonitis, history of gastrointestinal surgery, gastrointestinal colon cancer, gastrointestinal ulceration), hypomotility disorders (e.g., constipation, ileus, subileus, diabetic gastroparesis) and concomitant medications (e.g., calcium channel blockers); cases were reported in patients with no history of gastrointestinal disease; advise patients prescribed chewable tablets to chew tablet completely to reduce risk of serious adverse gastrointestinal events
Has radio-opaque properties and therefore may give the appearance typical of an imaging agent during abdominal X-ray procedures
Chewable tablets should be chewed completely to reduce the risk of serious adverse gastrointestinal events
Pregnancy & Lactation
Pregnancy Category: C
Lactation: use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Lanthanum forms strong complexes with PO4 that inhibits GI absorption and results in a decrease of serum phosphate and calcium levels
Half-Life, elimination: 53 hr (plasma); 2-3.6 years (bond)
Peak Plasma: 1 ng/mL
Protein bound: 99%
Metabolism: Not metabolized
Excretion: Predominantly feces
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs